Wu SJ, Wu CY, Ye K. Strategies for the comprehensive treatment of gastric cancer ovarian metastasis. World J Clin Oncol 2025; 16(6): 106589 [DOI: 10.5306/wjco.v16.i6.106589]
Corresponding Author of This Article
Kai Ye, MD, PhD, Associate Professor, Chief Physician, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Street, Quanzhou 362000, Fujian Province, China. medwcy@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2025; 16(6): 106589 Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.106589
Strategies for the comprehensive treatment of gastric cancer ovarian metastasis
Si-Jia Wu, Chu-Ying Wu, Kai Ye
Si-Jia Wu, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China
Chu-Ying Wu, Kai Ye, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China
Co-first authors: Si-Jia Wu and Chu-Ying Wu.
Author contributions: Wu SJ and Wu CY contributed equally to the study; Wu SJ contributed to original draft preparation, writing, and review; Wu CY contributed to writing, review, and editing; Y Kai contributed to conceptualization, supervision, and funding acquisition; All authors have read and agreed to the published version of the manuscript.
Supported by Quanzhou Science and Technology Plan Projects, No. 2024NY033; and Fujian Provincial Health and Youth Research Project, No. 2022QNA066.
Conflict-of-interest statement: All authors report no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai Ye, MD, PhD, Associate Professor, Chief Physician, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Street, Quanzhou 362000, Fujian Province, China. medwcy@163.com
Received: March 4, 2025 Revised: March 27, 2025 Accepted: May 7, 2025 Published online: June 24, 2025 Processing time: 110 Days and 17.3 Hours
Abstract
The incidence of gastric cancer is currently increasing, with gastrectomy and D2 Lymphadenectomy being the primary treatments for resectable gastric cancer. For advanced or unresectable metastatic gastric cancer, systemic treatment options include chemotherapy, targeted therapy, or immunotherapy. Krukenberg tumours are types of metastatic tumours in the ovaries that exclusively occur in female patients and that originate from the stomach. Previously deemed an incurable stage of advanced disease, the prognosis of patients with ovarian metastases from gastric cancer depends on multiple factors, including tumour biology and treatment response. With the development of comprehensive cancer treatment options, the combination of surgery and chemotherapy has gradually become the primary treatment for patients with ovarian metastasis from gastric cancer. Individualised comprehensive treatment regimens are crucial for improving patient outcomes. This review summarises the comprehensive treatment strategies for ovarian metastasis from gastric cancer.
Core Tip: Gastric cancer incidence is currently increasing, and treatments such as gastrectomy and D2 Lymphadenectomy are utilised for resectable patients, with chemotherapy, targeted therapy, or immunotherapy being used for advanced/metastatic patients. Krukenberg tumours (ovarian metastases in females with gastric cancer) were once incurable but are now primarily treated with surgery and chemotherapy. Individualised regimens are key to improving outcomes. This review outlines strategies for treating ovarian metastasis from gastric cancer.
